Abstract. A series of 53 organic chemicals belonging to the groups oforganic phosphates, sulfonyl derivatives and carbamates were screened for their activity against the coagulation factors IIu (thrombin), VII., IX" and Xu. Relatively specific inhibitors for the factors II", VII. and Xu were found.
Introduction
In the past decade, much progress has been made in the characterization of the molecular processes underlying blood coagulation (table I) . The activation reactions occurring in the coagulation pathways are highly specific, limited proteolysis reactions; the activated coagulation factors with the exception of factors V" and VIII. belong to the class of the serine proteases. When comparing the amino acid sequences around the active-site serine residues of the coagulation factors with those of the pancreatic enzymes chymotrypsin, trypsin and elastase, it can be seen that a high degree of sequence homology exists among these proteins [4] . Furthennore, thrombin and factor Xu contain histidine and asparagin residues in positions corresponding with the active-site histidine and asparagin residues present in trypsin and chymotrypsin. In the case of thrombin and factor Xu, the amino acid sequence of the active-site-bearing chain shows about /o sequence homology with trypsin. These data strongly suggest a close analogy between the coagulation factors and the pancreatic enzymes with respect to the activation of the zymogen and the catalytic mechanism of the active enzyme. Most likely, the substrate-binding pocket of the coagulation proteases will resemble that of trypsin because all coagulation proteases are specific towards basic amino acids (table I) .
The main differences between the coagulation factors and the digestive enzymes are the presence ofa second protein chain in the coagulation factors not involved in the catalytic reaction per se and, perhaps as a consequence ofthe occurrence ofthis additional protein part, the higher substrate specificity of the coagulation factors.
Of course, the tertiary structure of the coagulation factors can only be proven by crystallographic studies of these enzymes and their (natural) substrates, but valuable information can be obtained from work with model substrates. In these studies, small changes in the substrate structure can be introduced, and the effects on the enzyme-substrate interaction brought about by these small changes can give useful information about the substrate-binding site and the catalytic site of the enzymes. The same holds true for inhibitors.
The aim of the work presented here was to find specific inhibitors for the different coagulation factors. The availability of such specific inhibitors would be useful for the study of the mechanism of blood coagulation and for the chemical determination of the coagulation factors. The stereochemistry of the specific inhibitors could contribute to our knowledge of the structure of the active site of the coagulation factors, and finally, the specific inhibitors might possibly be used therapeutically. In the experiments described here, the inhibitory capacity towards the activated coagulation factors was checked for a series of organic compounds belonging to the organic phosphates, the sulfanyl derivatives and the carbamates. Other groups have used the same approach, but the families of inhibitors investigated here have, to our knowledge, not been screened before [13, 16, 30, 3l] .
Materials and Methods
Isolation and Purification of the Factors IIo, VII", IX, and Xo lsee also 401 As starting material, a coagulation factor concentrate containing the factors II, VII, IX, and X was prepared according to Swart [37] . The coagulation factor concentrate was activated with thromboplastin and Ca2*; the activated coagulation factors were separated by chromatography on a Whatman DE 32 column. (For the factors IIn and VII. the best results were obtained when the isolation was carried out at 4'C; for factor Xn the best results were obtained when the isolation occurred at room temperature.) It was not possible to obtain factor IXu by this procedure, presumably because the starting material did not contain a sufficient amount of this factor. However, when the coagulation factor concentrate was activated with contact product, a factor IXu preparation could be obtained. This preparation always contained factor XI" (from the contact product) and was only used in preliminary experiments. It was also possible to isolate a factor VII. -IXu * Xu concentrate from serum and to isolate the factors VII. and X" from this concentrate by chromatography on Sephadex G-100.
No attempt was made to obtain preparations that contained clotting factors that could be considered pure by the usual physicochemical criteria. Preparations that contained one coagulation factor in excess and no or trace activities ofthe others were considered su{Ii-ciently pure for our purposes. This is because the inhibitors are added in large molar excess anyhow, and the tests employed are sufficiently specihc not to be influenced by trace amounts of inhibited or uninhibited coagulation factors other than the one under investigatlon.
C oagul at io n F actor Reagents These reagents were prepared according lo Koller et al. [20] and Loeliger and Koller [2] (factorsVII and X); according lo Denson [5] (factorVII/X reagent). The factorVIII and factor IX reagents were obtained from a patient with a severe deficiency ofthe respective coagulation factor (< I 0/o activity) (440 ml blood collected in a siliconized glass vessel containing 60 ml ACD solution; storage at -20'C). Factor XI reagent was obtained from congenital factor XI deficient plasma.
Thromboplastin was prepared from human brain accordingto Owren and Aas 1321. Contact product was prepared according lo Niewiarowski et al. 1291 .
Determination of Coagulation Factors
For the estimation of the factors II, V, VII and X, one-stage estimations were carried out as describedby van der Meer et al. 126l ; the factors VIII and IX were estimated according to Veltkamp et al. l42l ; factor XI was estimated according lo Horowitz et al. I I 4] .
Determination of the Activated Coagulation Factors FactorII" was determined according to Hemker et al. [11] ; factorVll" in the same system as factorVll [26] but with phospholipids instead of thromboplastin: the factors VIII" and IX" in the same systems as used for factors VIII and IX [42] except that no kaolin was added to the test system and the incubation time of sample and reagent prior to recalcification was I min instead of 30 min; factor Xu was determined in a one-stage test with a factorVII and X deficient reagent and phospholipid [26] .
Inhibitors were the same as described by Meyers l27l and Meyers et al. [28] .
I nhibition Experiments
The coagulation factor (concentration about l0-6-10-r mol/l) was incubaled with the inhibitor (concentration about l0-2-10-+ mol/l) at pH 7 .4, 37 'C, in siliconized gJass or in plastic during 30 min (the concentrations of the coagulation factors were: thrombin.
Inhibition of Activated Clotting Factors 12.5 NIH U/ml; factor VII", 0.4-{.6 U/ml; factor IX", 0.15-0.25 U/ml; factor X", 0.5-0.75 U/ml; the final inhibitor concentration is given in tables II-V. If there was no or only a slight inhibition after 30min, the enzymatic activity was tested again. after 1,2,3 or, sometimes, 18 h.
All chemicals were p.a. grade from Merck. Protein concentrations were determined by measurirS Ezson. in a Zeiss PM Q I I spectrophotometer. It was assumed that for prothrombin and thrombin, I extinction unit at 280 nm corresponds with 1.6 mg protein/ml |7,371and for all other protein mixtures with I mg protein/ml [36] .
For a number of compounds the nuclear magnetic resonance (NMR) spectra were recorded in a Jeol PS 100 NMR apparatus; sweep time 250s, sweep width l,080Hz (X0.01 ppm). The organic compounds were dissolved in CDCIr; with the compounds No. l, 7, 13, and 30, a little deuterated aceton was added.
Results and Discussion
Within a series of related inhibitors that are all able to react with an active-site serine residue, the actual course ofthe reaction is determined by the stereochemistry of the enzyme around the aclive-site residue [21] . Therefore, it can be expected that the differences between the coagulation factors will be reflected in their susceptibility towards related inhibitors with varying chemical structure. As far as small substrates are considered, this is the same phenomenon that accounts for substrate specificity. For this reason, the interaction of series of serine esterase inhibitors with the factors II", VII., IXu, and Xa has been investigated.
The evaluation of the kinetic constants of the inhibition process was based on the following general scheme for the reaction of serine proteases with irreversible inhibitors. The inhibitors used in this study were first described by 27] who tested their inhibitory activity towards acetylcholine esterases; their chemical structure is given in table IL Table II summarizes the results of a first screening of the inhibitory activity of the tested compounds towards the factors IIu, VII., IX" and Xu. The k3s values given in table II were calculated af,ter a fixed constant time interval (30 min) without a control of the actual time course of the inactivation and, therefore, must be considered as a rough estimation of the inhibitory capacity of the compounds under consideration.
The compounds that seemed to be good and/or specific inhibitors during this first screening were tested again with the factors IIu, VII', IXu, and Xu, but this time the inhibitor concentration was the same with all four coagulation factors. The purity of the compounds used for this second screening was also checked by NMR spectroscopy. All compounds except compounds No. 13, 16, and 35 had a purity of at least 97 o/o; the compounds No. 13, 16, and 35 seemed to be partially degraded. The results of this second screening are shown in italics in table II.
In order to facilitate the evaluation of the inhibitory capacity of the compounds tested, the kuoo values for the inhibition of the coagulation factors with diisopropylfluorophosphate (DFP) are given in table III. Table II No.
Chemical structure of the inhibitor lo "+l-\ F-P-NH-< ') As judged from table II, there seem to occur rather specific inhibitors for the different coagulation factors among the organic compounds tested. The inhibitors that gave k3e values of 50 X l0-a min-r in these screenings were used further to determine the krz and K values of the inactivation processes (see below). As the data on the ineffective inhibitors gave information on the active site as well, we did not omit the negative results.
Tables IV-VI give the kinetic constants of the interaction of the factors IIu, VIIa, and Xu, respectively, with their more or less specific inhibitors. For the determination of the k*2 and lli values given in these tables, samples were taken from the incubation mixture at different times and the residual activity was measured. k*2 and K values were calculated as described above. By sampling from the incubation mixture and dilution with the substrate, the velocity of the inhibition reaction decreases and competition between the inhibitor and natural substrate occurs. Because of this dilution, and because the clotting times are short compared to the incubation times, it can be assumed that the inactivation reaction does not proceed further during the clotting test. For the same reasons' the inhibition of thromboplastin and of the coagulation factors in the reagent by the inhibitor during the activity determination can be neglected.
As can be deduced from When comparing the tables IV, V, and VI, it is striking that the 'specific' inhibitors all belong to the class of the organic phosphorus com- As can be seen in the general scheme for the reaction of serine proteases with irreversible inhibitors given above, the inhibitor ltrst forms a reversible complex with the enzyme [E ' I] which is further converted into an irreversible complex [Einniui,"o] . K1 reflects the affinity of the enzyme for the substrate, and kz is the reaction velocity of the irreversible step-As can be seen in table IV, the compounds with a G"'G"'-group in the R2 position give relatively large k2 values; the smallest K1 values are found with the compounds which do not have aromatic groups in the R2 portion.
From the results presented above it is clear that also small synthetic compounds can discriminate between the closely related compounds thrombin, factor VII. and factor Xu. The same conclusion was reached by other groups. Okamoto et al. [30] studied a series of thrombin inhibitors belonging to No-naphtalenesulfonyl-I-argine derivates. The structure of these inhibitors is characterized by three entities: a positively charged group (the amino acid argine), an aromatic group (the dansyl group, attached to the cr-NHz group of arginine), and a hydrophobic carbon chain (attached to the carboxyl group of arginine; optimal chain length 3 or 4 C-atoms). These authors reported I5s values for these compounds in the range from 0.03 to 2 pmol/l when frbrinogen (3 pmol/l) or N"-benzoyl-Z-phenylalanyl-l-valyl-I-aryinine-p-nitroanilide (100 pmol/l) is used as a substrate. These values are of the same order of magnitude as the K1 values described in this article. Kettner and Shaw [16] reported inactivation experiments of thrombin by tetra-and tripeptide argine chloromethyl ketones. The peptide part of these substrates contains the amino acid sequence at the site cleaved by thrombin in its physiological substrates. The compounds Val-Pro-Arg-CHzCl (analog of the factor XIII cleavage site) and Ile-Pro-Arg-CHrCl (analog of the pro- thrombin cleavage site) inactiYate thrombin by 500/o in less than 25 min at a concentration of 7.5 X I 0-8 M. The compound Gly-Val-Arg-CH2Cl [analog ofthe cleavage site in the fibrinogen A (o) chainl was effective at a concentration of 2 X 10-6 moVl. The authors reported that the compounds with the proline residue in the P2 composition were markedly more reactive with thrombin than with plasma kallikrein, plasmin, urokinase, and factor Xo. Markwardt [25] described irreversible thrombin inhibitors derived from the competitive inhibitors benzylamine and benzamidine by introduction of a reactive fluorosulfonyl moiety at the aromatic ring. These compounds, aminomethyl and amidinofluorosulfonylbenzenes, possessed an inhibitory effect towards thrombin that surpassed that of DFP and phenylmethyl sulfonylfluoride (PMSD. 
